赖氨酰氧化酶样2在哮喘中升高并参与气道重塑
该研究结合体外人气道平滑肌细胞与体内OVA哮喘小鼠模型,发现哮喘气道平滑肌细胞中LOXL2表达增加,且LOXL2抑制可降低ECM硬度与TGF-β激活,并在小鼠中减少上皮下胶原沉积与平滑肌厚度。
要点
- 哮喘气道平滑肌细胞中LOXL2表达增加
- LOXL2抑制可降低ECM硬度和TGF-β激活
- LOXL2抑制减少小鼠气道重塑特征
核心结论
- LOXL2在哮喘气道重塑中发挥作用,抑制LOXL2可能成为减少重症哮喘气道重塑的潜在疗法。
研究设计与样本
- 研究结合体外人气道平滑肌细胞实验与体内慢性卵清蛋白(OVA)哮喘小鼠模型,并使用哮喘与非哮喘供体支气管活检组织。
主要发现
- 哮喘气道平滑肌细胞基础TGF-β激活高于非哮喘对照,且疾病细胞来源的ECM影响TGF-β激活水平。
- LOXL2在哮喘气道平滑肌细胞和支气管活检中表达增加。
- 体外抑制LOXL2可降低ECM硬度和TGF-β激活。
- OVA哮喘小鼠模型中抑制LOXL2可减少上皮下胶原沉积和平滑肌厚度。
临床怎么用
- LOXL2抑制值得进一步研究作为减少重症哮喘气道重塑的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Airway smooth muscle (ASM) cells are fundamental to asthma pathogenesis, influencing bronchoconstriction, airway hyperresponsiveness and airway remodelling. The extracellular matrix (ECM) can influence tissue remodelling pathways; however, to date no study has investigated the effect of ASM ECM stiffness and cross-linking on the development of asthmatic airway remodelling. We hypothesised that transforming growth factor-β (TGF-β) activation by ASM cells is influenced by ECM in asthma and sought to investigate the mechanisms involved. METHODS: This study combines in vitro and in vivo approaches: human ASM cells were used in vitro to investigate basal TGF-β activation and expression of ECM cross-linking enzymes. Human bronchial biopsies from asthmatic and nonasthmatic donors were used to confirm lysyl oxidase like 2 (LOXL2) expression in ASM. A chronic ovalbumin (OVA) model of asthma was used to study the effect of LOXL2 inhibition on airway remodelling. RESULTS: We found that asthmatic ASM cells activated more TGF-β basally than nonasthmatic controls and that diseased cell-derived ECM influences levels of TGF-β activated. Our data demonstrate that the ECM cross-linking enzyme LOXL2 is increased in asthmatic ASM cells and in bronchial biopsies. Crucially, we show that LOXL2 inhibition reduces ECM stiffness and TGF-β activation in vitro, and can reduce subepithelial collagen deposition and ASM thickness, two features of airway remodelling, in an OVA mouse model of asthma. CONCLUSION: These data are the first to highlight a role for LOXL2 in the development of asthmatic airway remodelling and suggest that LOXL2 inhibition warrants further investigation as a potential therapy to reduce remodelling of the airways in severe asthma.
引用
- Ramis J, Middlewick R, Pappalardo F, et al. Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling. Eur Respir J. 2022. PMID: 34996828. doi:10.1183/13993003.04361-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。